The Reporting of A Disproportionality analysis for drUg Safety signal detection using spontaneously reported adverse events in PharmacoVigilance (READUS-PV)

被引：0
|
作者：
Fusaroli, M. [1 ]
Raschi, E. [1 ]
Salvo, F. [2 ]
Khouri, C. [3 ]
机构：
[1] Univ Bologna, Dept Med & Surg Sci, Pharmacol Unit, Bologna, Italy
[2] CHU Bordeaux, Serv Pharmacol Med, Bordeaux, France
[3] Grenoble Alpes Univ Hosp, Pharmacovigilance Unit, Grenoble, France
来源：
FUNDAMENTAL & CLINICAL PHARMACOLOGY | 2023年 / 37卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
CO-060
引用
收藏
页码：43 / 43
页数：1
相关论文
共 50 条
  • [21] Disproportionality analysis of vibegron-associated adverse events using the FDA adverse event reporting system (FAERS): a real-world pharmacovigilance study
    Bangbei Wan
    Zhi Zhou
    Ning Ma
    Weiying Lu
    European Journal of Medical Research, 30 (1)
  • [22] A safety signal of venous thromboembolic events with the use of DPP-4 inhibitors: a pharmacovigilance disproportionality analysis
    Gouverneur, A.
    Lair, A.
    Arnaud, M.
    Begaud, B.
    Thiessard, F.
    Pariente, A.
    Salvo, F.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2018, 32 : 30 - 30
  • [23] Disproportionality analysis of spontaneously reported hypoglycemia events due to insulin use: A comparison between insulin detemir and insulin degludec using the Korea Adverse Event Reporting System
    Jeong, DaWo
    Kim, Won
    Shin, Ju-Young
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2021, 59 (03) : 224 - 230
  • [24] A safety signal of venous thromboembolic events with the use of DPP-4 inhibitors: A pharmacovigilance disproportionality analysis
    Gouverneur, Amandine
    Lair, Athenais
    Arnaud, Mickael
    Begaud, Bernard
    Thiessard, Frantz
    Pariente, Antoine
    Salvo, Francesco
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2018, 27 : 38 - 38
  • [25] Ocular adverse events associated with BRAF and MEK inhibitor combination therapy: a pharmacovigilance disproportionality analysis of the FDA adverse event reporting system
    Huang, Shuohan
    Guo, Zihan
    Wang, Mengmeng
    She, Youjun
    Ye, Xuan
    Zhai, Qing
    Liu, Jiyong
    Du, Qiong
    EXPERT OPINION ON DRUG SAFETY, 2023, 22 (02) : 175 - 181
  • [26] Analysis of Spontaneously Reported Adverse Drug Events: Towards Developing Systems for Preventability
    Ketor, Courage Edem
    Benneh, Charles Kwaku
    Sarkodie, Emmanuel
    Anaglo, Juliet Ama
    Mensah, Adelaide
    Somuah, Samuel Owusu
    Akakpo, Selorm
    Woode, Eric
    BIOMED RESEARCH INTERNATIONAL, 2024, 2024
  • [27] A DISPROPORTIONALITY ANALYSIS OF THE SERIOUS ADVERSE DRUG EVENTS ASSOCIATED WITH GENE THERAPY PRODUCTS USING THE FDA ADVERSE EVENT REPORTING SYSTEM (FAERS)
    Ghanem, B.
    Fleming, M.
    Brown, L. M.
    Rodriguez-Monguio, R.
    Seoane-Vazquez, E.
    VALUE IN HEALTH, 2023, 26 (06) : S237 - S237
  • [28] A Disproportionality Analysis of the Adverse Drug Events Associated with Lurasidone in Paediatric Patients Using the US FDA Adverse Event Reporting System (FAERS)
    Rees, Kate E.
    Chyou, Te-yuan
    Nishtala, Prasad S.
    DRUG SAFETY, 2020, 43 (06) : 607 - 609
  • [29] A Disproportionality Analysis of the Adverse Drug Events Associated with Lurasidone in Paediatric Patients Using the US FDA Adverse Event Reporting System (FAERS)
    Kate E. Rees
    Te-yuan Chyou
    Prasad S. Nishtala
    Drug Safety, 2020, 43 : 607 - 609
  • [30] Serious adverse events reported with benzimidazole derivatives: A disproportionality analysis from the World Health Organization's pharmacovigilance database
    Modingam, Pamella
    Faillie, Jean-Luc
    Campillo, Jeremy T.
    PLOS NEGLECTED TROPICAL DISEASES, 2024, 18 (11):
12345